Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (651)	4/30/2004 3:17:02 PM
From: tuck	of 897

My goodness, I hadn't noticed that Hemispherx (HEB) had actually gotten above $5. It seems to be tanking today with the market, but I'm putting it on the WatchList . . . >>PHILADELPHIA--(BUSINESS WIRE)--April 30, 2004-- Hemispherx Biopharma, Inc. (AMEX:HEB - News) announced today that it has accelerated the presentation of the primary endpoint data of its Ampligen study in Chronic Fatigue Syndrome (CFS). The Company has moved up the presentation date to May 3, 2004 instead of the originally scheduled date of May 6, 2004. The presentation will take place at the 17th International Conference on Antiviral Research. << snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next